報價延遲最少15分鐘:2026/01/09 09:42 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.66/-0.33
|
|
企業價值
17.38M
|
| 資產負債 |
|
每股賬面淨值
0.12
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
705.92K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology. |
